Bacteriological Study of Proteus mirabilis Isolated from Different Clinical Samples
DOI:
https://doi.org/10.46966/msjar.v5i1.165Abstract
Abstract: This study focuses on isolating and identifying 17 strains of Proteus mirabilis from a total of 135 clinical samples obtained from patients who visited Hila Teaching Hospital between October 2014 and February 2015. The isolates collected from patients diagnosed with urinary tract infections accounted for 11 cases or 64.7% of the total. In contrast, patients with ear infections contributed 3 cases, making up 17.6% of the total. In addition, the isolates acquired from patients with diarrhea, wound, and vaginal infection each accounted for 1 (5.9%) of the total cases. The collected isolates have been cultivated on specialized media and identified using biochemical reactions.
Some virulence factors of all isolates are studied, and the results showed that all bacterial isolates 17(100%) produced hemolysin, urease, Bacteriocin (proticin), and swarming, while 16(94.1%) of isolate produced beta-lactamase. Antibiogram of P. mirabilis isolates has been studied and it has been found that all isolates were entirely resistant to Imipenem 17(100%), while most of the P. mirabilis isolates were sensitive to Ertapenem so the resistant only 3(17.6%). Furthermore, the resistance of isolates to Amoxicillin and Cefotaxime 14(82.3%), also 9(52.9%) of them were resistant to Amoxiclave, 11(64.7%) of them were resistant to Ceftriaxone and 4(23.5%) of them were resistant to Cefepime Clavulanic acid.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ameer S. Albujassim, Sumaya NajimAbedali Al-khateeb, Hashim Alsherees, Inam abid Aljabar Rasool, Rana Talib Al-Nafakh, Saif jabbar Yasir, Raad Abdulameer Alasady, Wijdan Rajh Hamza Al-Kraity
This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
